This site is intended for US healthcare professionals only.

    is NOW FDA-APPROVED
    for the treatment of adult patients with relapsed or refractory dif‌fuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

    Contact your XPOVIO® (selinexor) representative to learn more.

    Reference: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; July 2019.